Data from 17 international registries (JAK-pot collaboration) suggest that for Rheumatoid arthritis (RA) patients failing their first janus kinase inhibitor (JAKi), it did not matter if they were cycled to another JAKi or switched to a biologic disease-modifying antirheumatic drug (bDMARD).
A cross-sectional global study shows a substantial impact of obesity and BMI on the health and economic impact of patients with musculoskeletal (MSK) disorders.
Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said.
A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy.
People at high risk of fracture who also have complex or multiple chronic medical conditions are less likely to receive treatment for the underlying osteoporosis and also have poorer health outcomes, according to a new study from the Garvan Institute of Medical Research.
Nearly all available vaccines can be given to people with rheumatologic diseases, according to a new, detailed guideline from the American College of Rheumatology (ACR), though the timing for their administration and dosing of antirheumatic drugs may need adjustment in some cases.
A Longitudinal Swedish study has shown that elevated serum uric acid (SUA) levels has cardiovascular implications and may predict the development of atrial fibrillation (AFib).